ETON Stock Analysis: Eton Pharmaceuticals | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.712m USD | 12M Return: 262.7% | US29772L1089 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 30.2M
Qual. Beats: 1
Rev. Trend: 95.7%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 7.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is a U.S.-based pharmaceutical company headquartered in Deer Park, Illinois, that develops and commercializes treatments for rare diseases. The company was incorporated in 2017 and went public in November 2018.
Its commercial portfolio includes Increlex (severe primary IGF-1 deficiency), Alkindi Sprinkle and Khindivi (adrenal insufficiency), Galzin (Wilson disease), PKU Golike (phenylketonuria), Carglumic Acid (N-acetylglutamate synthase deficiency), Betaine Anhydrous (homocystinuria), and Nitisinone (tyrosinemia type 1). Several of these products were acquired or in-licensed rather than discovered in-house, which is a common approach in the rare disease space where small patient populations make in-licensing and niche commercialization more efficient than large-scale R&D.
Etons late-stage pipeline includes ET-600 (diabetes insipidus), Amglidia (neonatal diabetes mellitus), ET-700 (Wilson disease), ET-800 (adrenal insufficiency), and the ZENEO hydrocortisone autoinjector (adrenal crisis). Because rare disease therapeutics typically benefit from orphan drug designation, the company can pursue expedited regulatory pathways and extended market exclusivity, supporting a specialty business model focused on small patient populations with limited treatment options.
- Rare disease product revenue scales with Increlex and Alkindi adoption
- Late-stage pipeline approvals for ET-600 Amglidia ZENEO autoinjector drive upside
- Reimbursement and pricing pressure on rare disease therapeutics compresses margins
| Net Income: 12.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 0.70 > 1.0 |
| NWC/Revenue: 22.23% < 20% (prev 51.30%; Δ -29.07% < -1%) |
| CFO/TA 0.13 > 3% & CFO 15.1m > Net Income 12.7m |
| Net Debt (2.58m) to EBITDA (20.4m): 0.13 < 3 |
| Current Ratio: 1.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.8m) vs 12m ago 21.92% < -2% |
| Gross Margin: 57.87% > 18% (prev 59.41%; Δ -1.54% > 0.5%) |
| Asset Turnover: 97.11% > 50% (prev 57.22%; Δ 39.88% > 0%) |
| Interest Coverage Ratio: 3.76 > 6 (EBIT TTM 16.3m / Interest Expense TTM 4.34m) |
| A: 0.20 (Total Current Assets 68.6m - Total Current Liabilities 45.1m) / Total Assets 115.8m |
| B: -0.86 (Retained Earnings -99.4m / Total Assets 115.8m) |
| C: 0.15 (EBIT TTM 16.3m / Avg Total Assets 108.7m) |
| D: 0.67 (Book Value of Equity 46.6m / Total Liabilities 69.2m) |
| Altman-Z'' = 0.25 = B |
| DSRI: 0.95 (Receivables 24.9m/14.5m, Revenue 105.6m/58.2m) |
| GMI: 1.03 (GM 59.41% / 57.87%) |
| AQI: 1.22 (AQ_t 0.39 / AQ_t-1 0.32) |
| SGI: 1.81 (Revenue 105.6m / 58.2m) |
| TATA: -0.02 (NI 12.7m - CFO 15.1m) / TA 115.8m) |
| Beneish M = -2.33 (Cap -4..+1) = BBB |
As of August 28, 2026, the stock is trading at USD 62.67 with a total of 445,866 shares traded. Over the past week, the price has changed by +4.61%, over one month by +48.12%, over three months by +93.43% and over the past year by +262.67%.
Current recommended Stop Loss: 58.40 (which is 6.8% or 1.2 ATR below the current price).
Eton Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ETON.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 71 | 13.3% |
P/E Trailing = 157.6579
P/E Forward = 45.4545
P/S = 16.2168
P/B = 37.7223
Revenue TTM = 105.6m USD
EBIT TTM = 16.3m USD
EBITDA TTM = 20.4m USD
Long Term Debt = 21.8m USD (from longTermDebt, last fiscal year)
Short Term Debt = 8.82m USD (from shortTermDebt, last quarter)
Debt = 29.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 440k
Net Debt = 2.58m USD (calculated: Debt 29.4m - CCE 26.8m)
Enterprise Value = 1.71b USD (1.71b + Debt 29.4m - CCE 26.8m)
Interest Coverage Ratio = 3.76 (Ebit TTM 16.3m / Interest Expense TTM 4.34m)
EV/FCF = 116.4x (Enterprise Value 1.71b / FCF TTM 14.7m)
FCF Yield = 0.86% (FCF TTM 14.7m / Enterprise Value 1.71b)
FCF Margin = 13.95% (FCF TTM 14.7m / Revenue TTM 105.6m)
Net Margin = 12.02% (Net Income TTM 12.7m / Revenue TTM 105.6m)
Gross Margin = 57.87% ((Revenue TTM 105.6m - Cost of Revenue TTM 44.5m) / Revenue TTM)
Gross Margin QoQ = 67.61% (prev 60.72%)
Tobins Q-Ratio = 14.81 (Enterprise Value 1.71b / Total Assets 115.8m)
Interest Expense / Debt = 14.74% (Interest Expense 4.34m / Debt 29.4m)
Taxrate = 0.49% (63.0k / 12.8m)
NOPAT = 16.2m (EBIT 16.3m * (1 - 0.49%))
Current Ratio = 1.52 (Total Current Assets 68.6m / Total Current Liabilities 45.1m)
Debt / Equity = 0.63 (Debt 29.4m / totalStockholderEquity, last quarter 46.6m)
Debt / EBITDA = 0.13 (Net Debt 2.58m / EBITDA 20.4m)
Debt / FCF = 0.18 (Net Debt 2.58m / FCF TTM 14.7m)
Total Stockholder Equity = 31.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.67% (Net Income 12.7m / Total Assets 115.8m)
RoE = 40.13% (Net Income TTM 12.7m / Total Stockholder Equity 31.6m)
RoCE = 30.55% (EBIT 16.3m / Capital Employed (Equity 31.6m + L.T.Debt 21.8m))
RoIC = 21.86% (NOPAT 16.2m / Invested Capital 74.2m)
WACC = 6.35% (E(1.71b)/V(1.74b) * Re(6.21%) + D(29.4m)/V(1.74b) * Rd(14.74%) * (1-Tc(0.00)))
Discount Rate = 6.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 80.35 | Cagr: 11.31%
[DCF] Terminal Value 77.97% ; FCFF base≈13.7m ; Y1≈15.7m ; Y5≈23.2m
[DCF] Fair Price = 12.10 (EV 348.5m - Net Debt 2.58m = Equity 346.0m / Shares 28.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: 95.67 | Revenue CAGR: 60.15% | SUE: 4.0 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.37 | Chg30d=+19.35% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=1.40 | Chg30d=+38.61% | Revisions=+25% | GrowthEPS=+337.5% | GrowthRev=+87.2%
EPS next Year (2027-12-31): EPS=2.58 | Chg30d=+37.23% | Revisions=+25% | GrowthEPS=+84.3% | GrowthRev=+46.9%
[Analyst] Revisions Ratio: +50% (up=3, down=0)